Given their critical role in cancer progression, cadherins are considered potential therapeutic targets. Strategies to restore E-cadherin function or inhibit N-cadherin interactions are being explored. For example, small molecules and monoclonal antibodies that block N-cadherin function are in preclinical and clinical development. Additionally, epigenetic drugs that restore E-cadherin expression are being investigated.
